Protein Expression Markers for the Detection of Thyroid Cancer Metastasis

Description (Set) Approximately 80% of all thyroid cancers are papillary thyroid carcinomas (PTCs). Correct staging of PTC is one of the most important parts of the work up of patients for both prediction of outcome and determination of the most appropriate treatment. PTC generally has a high cure rate with standard surgical and adjuvant radioiodine treatment of neck lymph node metastases (LNM) which are found in 30-65% of initial diagnoses of PTCs. Fifteen percent of cases with LNMs also display extremely aggressive behavior, characterized by local invasion, distant metastasis, treatment resistance, and increased mortality. Because of this low percentage of LNMs with aggressive behavior, the management of PTCs is often controversial and depends on the detection of distant metastases. Scientists at Johns Hopkins University have identified three biomarkers that appear in metastatic cells of thyroid cancer but not in primary tumors. These markers can be used to provide an improved means to detect metastatic Papillary Thyroid Carcinoma cells during initial staging of a newly diagnosed carcinoma and/or to rule out recurrence. Proposed Use (Set) Currently, it is difficult to determine if patients have a recurrence of thyroid cancer, and present markers are not useful in a large proportion of patients with this cancer. These markers have the potential of being useful for a much larger percentage of patients and also to help staging of a newly diagnosed patient to help detect occult metastasis, as well as predict the malignant and potential of the primary tumor.

Inventor(s): Riggins, Gregory ,Cerutti, Janete

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent